ClinicalTrials.gg
RecruitingNCT06928922Updated Oct 26, 2026

mRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors

An Early Phase 1 interventional study of BMD006 monotherapy and BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation) in Advanced Lung Cancer and Lung Metastasis, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged Up to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Updated Oct 26, 2026Interventions changedTitle changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
Up to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 10 open to participants now, 11 under way, none of them phase 3. Lung Neoplasms · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Planned enrollment
6th of 13
83 · median 80
Started
2025
with 1 other
Phase 1
Only one
of the 19
Primary completion
2027-02
later than 6 of 10 live
Registered
14th of 19
by date

Among the 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 1, reaches primary completion later than 6 of the 10 other live ones, and was the 14th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: Up to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, or all of them as a file.
02

Study summary

BMD006 is an off-the-shelf antitumor mRNA vaccine targeting lung cancer and lung metastatic solid tumors.

This is a single-center, open-label, dose-escalation clinical trial. The study aims to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of BMD006 in patients with advanced lung cancer or advanced solid tumors with lung metastasis who have progressed on or are ineligible for standard therapeutic options. This trial also further explores the clinical efficacy of BMD006 in combination with Immuno-Oncology (IO) therapy.

Read the detailed description

This is a single-center, open-label, dose-escalation trial designed to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of BMD006 in patients with advanced lung cancer or advanced solid tumors with lung metastasis who have progressed on or have no available standard treatment options. In addition, this study aims to explore the clinical efficacy of BMC001 in combination with Immuno-Oncology (IO) therapy.

The trial comprises three study arms: BMD006 monotherapy dose escalation, BMD006 plus IO therapy dose escalation, and BMD006 plus IO therapy dose expansion.

03

Conditions studied

  • Advanced Lung Cancer
  • Lung Metastasis

Keywords

  • mRNA vaccine
  • advanced lung cancer
  • solid tumors with lung metastasis
  • mRNA vaccine combined with Immuno-Oncology (IO) therapy
04

Who can participate

Ages eligible
Up to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and comply with the requirements of the study protocol, voluntarily participate in the trial, and sign a written form (ICF).
  • Must be at least 18 (inclusive) at the time of signing the ICF, and both male and female participants are eligible.
  • or cytologically confirmed as advanced lung cancer (driver gene negative) or advanced solid tumors with lung , and having failed prior standard treatments or having no standard treatment options.
  • Agree to provide fresh tumor tissue samples or archived tumor tissue samples within the past three years.
  • Presence of at least one as defined by V1.1
  • performance status (ECOG PS) of 0-1
  • Organ function must be adequate at screening (no need for blood transfusion, hematopoietic growth factors, human albumin, or medications for correction within 14 days prior to first treatment), specifically defined as: a) Hematology: ≥1.5×10\^9/L; count ≥90×10\^9/L; ≥90 g/L (9 g/dL). b) Liver Function: Serum total (TBIL) ≤1.5× (ULN); for patients with liver metastasis or a history/suspected history of Gilbert's syndrome (persistent or recurrent hyperbilirubinemia, primarily unconjugated bilirubin, with no evidence of hemolysis or liver pathology), TBIL ≤3×ULN; for patients without liver metastasis, (ALT) and aspartate aminotransferase (AST); for patients with liver metastasis, ALT or AST ≤5×ULN. c) Renal Function: Creatinine (Cr) ≤1.5×ULN or (CLcr) ≥60 mL/min (calculated using the Cockcroft-Gault formula, see Attachment 3); urine dipstick test result showing urinary protein \<2+; for patients with baseline urine dipstick showing protein ≥2+, a 24-hour urine collection should be conducted, and the protein content in the 24-hour urine should be \<1 g. d) Cardiac Function: Echocardiography showing (LVEF) >50%. e) Pulmonary Function: Shortness of breath ≤Grade 1 as per the National Cancer Institute (NCI CTCAE), and outdoor ambient air oxygen saturation (SpO₂) ≥92%.
  • Expected ≥12 weeks.
  • Female patients of and male patients (and their female partners) must use highly effective from the screening period until at least 6 months after the last dose of the study drug. Patients must not plan to conceive, donate sperm, or donate eggs during this period

Exclusion criteria

Exclusion Criteria:

  • Patients with lung cancer who have concurrent other types of malignant tumors or are diagnosed with multiple primary , except for the following: completely resected basal cell carcinoma and squamous cell carcinoma of the skin, completely resected any type of carcinoma in situ.
  • Symptomatic central nervous system ; for patients with asymptomatic or those whose symptoms have been stable for ≥2 weeks after treatment of brain metastasis, they may participate in this study if they meet all the following criteria: in the lungs; cessation of treatment 14 days prior to the first trial product dose.
  • Patients with (COPD), asthma, or allergies to pollen or dust.
  • Patients suspected of having active or latent tuberculosis infection, based on interferon-γ release assay results, clinical symptoms, and/or chest imaging findings (patients with evidence of adequately treated prior active tuberculosis infection may be enrolled after assessment by the investigator; for latent tuberculosis, patients must have completed at least 4 weeks of anti-tuberculosis treatment, with no liver function impairment [ ≤3×, AST ≤3×ULN], and after the investigator assesses that the risk is manageable, they may be considered for continued screening or enrollment).
  • History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis or organizing pneumonia), or active, non-infectious pneumonia requiring treatment such as corticosteroids.
  • Patients with active diseases requiring therapeutic intervention.
  • History of serious bleeding disorders; or those with coagulation dysfunction (as indicated by laboratory tests or medical history) who are deemed by the investigator to be unsuitable for the trial treatment.
  • History or current diagnosis of cardiovascular disease, including any of the following: a) Recent myocardial infarction or coronary artery bypass grafting (CABG) within the past 6 months; b) Uncontrolled congestive heart failure; c) Unstable angina (within the past 6 months); d) (symptomatic) arrhythmias (e.g., sustained ventricular tachycardia, clinically significant second- or third-degree atrioventricular block without a pacemaker).
  • Clinically uncontrolled third-space fluid accumulation (e.g., pleural effusion/pericardial effusion; patients with effusions that do not require drainage or those whose effusions have not increased significantly after stopping drainage for 3 days may be included).
  • Severe infection requiring intravenous antibiotic treatment or hospitalization at screening, or any uncontrolled active infection within 4 weeks prior to the first dose of the trial product.
  • History of severe allergic reactions, or known allergy to any active or inactive component of BMD006 or inhibitors.
  • Any other metabolic, hematological, renal, hepatic, pulmonary, neurological, endocrine, cardiac, or gastrointestinal disease that, in the investigator's opinion, may present unacceptable risks to the patient during treatment.
  • Presence of unresolved toxicity from prior anti-tumor treatments before the first dose of the study product, which has not recovered to Grade 0 or 1 (excluding alopecia) (severity assessed according to v5.0).
  • Positive test results for at screening [defined as: ① Hepatitis B surface antigen (HBsAg) positive; ② HBsAg negative but hepatitis B core antibody (HbcAb) positive (further testing through hepatitis B virus deoxyribonucleic acid [HBV DNA] is required, and patients with HBV DNA levels exceeding the normal limit for the test method must be excluded)], positive antibody (HCV Ab) [further testing through hepatitis C virus ribonucleic acid (HCV RNA) is required, and patients with HCV RNA levels exceeding the normal limit for the test method must be excluded], or positive antibody (HIV Ab).
  • Underwent major surgery within 4 weeks prior to the first dose of the trial product (cranial, thoracic, or abdominal surgery) or has an unresolved wound, ulcer, or fracture. Note: Thoracoscopic surgery and mediastinoscopy will not be considered major surgery. Patients who are ≥2 weeks post-surgery or who are deemed eligible by the investigator may be included in the study.
  • Previously received similar products or treatments.
  • Received other anti-tumor treatments (radiotherapy, chemotherapy, endocrine therapy, targeted therapy, immunotherapy, etc.) within 4 weeks or 5 half-lives (whichever is longer) prior to the first dose of the trial product.
  • Received systemic immunosuppressive agents (e.g., systemic corticosteroids) within 3 months prior to the first dose of the trial product.
  • Received or planned to receive live or attenuated within 3 months prior to the first dose of the trial product or during the study.
  • Pregnant or breastfeeding women.
  • Participated in any clinical drug trial (defined as being randomized and receiving trial product treatment) within 3 months or 5 half-lives (whichever is longer) prior to screening.
  • Any other condition deemed by the investigator to make the patient unsuitable for participation in the trial.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
83 participants (estimated)

Study arms

  • Experimental
    BMD006 monotherapy

    In this trial, patients receive BMD006 monotherapy. The investigators will assess the safety and tolerability of the treatment. Eligible patients will continue to receive treatment at the assigned dose until 52 weeks after the first administration or until meeting the study termination criteria.

    Biological: BMD006 monotherapy

  • Experimental
    BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation)

    For the cohort of BMD006 in combination with Immuno-Oncology, investigators will assess the safety and tolerability of the treatment. Eligible patients will continue to receive treatment at the assigned dose until 52 weeks after the first administration or until meeting the study termination criteria.

    Biological: BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation)

  • Experimental
    BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Expansion)

    Subjects will be assigned to either the BMD006 plus IO therapy group (Group 1) or the BMD006 monotherapy followed by IO combination therapy group (Group 2). Group 1 receives combination therapy with BMD006 and IO therapy. Group 2 receives BMD006 monotherapy initially; after the initial treatment phase, investigators will assess potential clinical benefits, and then IO therapy will be added for combined treatment.

    Biological: BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Expansion)

Interventions

  • BiologicalBMD006 monotherapy

    Following the initial BMD006 administration, subjects will undergo DLT observation for single treatment. If investigators confirm acceptable safety and tolerability, subjects will enter DLT observation for multiple treatment. After satisfactory safety assessment, subjects will continue treatment at the assigned dose until 52 weeks after the first administration or until meeting treatment discontinuation criteria.

  • BiologicalBMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation)

    Once the dose escalation of BMD006 monotherapy is completed and the MTD (Maximum Tolerated Dose) is determined (i.e., the RP2D for this study), dose escalation exploration of BMD006 in combination with Immuno-Oncology (IO) therapy will be initiated. Subjects will undergo DLT observation. If investigators confirm acceptable safety and tolerability, subjects will continue treatment at the assigned dose until 52 weeks after the first administration or until meeting treatment discontinuation criteria.

  • BiologicalBMD006 in combination with Immuno-Oncology (IO) therapy (Dose Expansion)

    Group 1 receives combination therapy with BMD006 and Immuno-Oncology (IO) therapy. Group 2 receives BMD006 monotherapy initially. After the initial treatment phase, investigators will assess potential clinical benefits, and IO therapy will be added for combined treatment thereafter.

06

What researchers measure

Primary outcomes

  1. Number of participants experiencing dose-limiting toxicities(DLTs)

    Number of participants experiencing dose-limiting toxicities(DLTs)

    Time frame: about 2 years

  2. Determine the maximum tolerated dose(MTD) of BMD006

    Determine the maximum tolerated dose(MTD) of BMD006

    Time frame: about 2 years

  3. Determine the recommended phase II dose (RP2D) for the clinical study.

    Determine the recommended phase II dose (RP2D) for the clinical study.

    Time frame: about 2 years

  4. number of participants experiencing adverse events(AEs)

    number of participants experiencing adverse events(AEs)

    Time frame: about 2 years

Secondary outcomes

  1. overall response rate(ORR)

    The percentage of patients who achieved the best overall response of complete response (CR) or partial response (PR) as evaluated by investigators based on RECIST V1.1

    Time frame: Up to 12 months

  2. Disease Control Rate(DCR)

    The percentage of patients who achieved CR, PR, or SD)as assessed by investigators based on RECIST V1.1.

    Time frame: Up to 12 months

  3. Duration of Response(DOR)

    The investigators evaluated the time from objective remission to the first recorded disease progression or death (whichever occurred first) based on RECIST V1.1;

    Time frame: Up to 12 months

  4. Progression-Free Survival (PFS)

    The time between the first treatment date and the date of the first recorded disease progression or death (whichever occurs first) evaluated by the investigator according to RECIST V1.1;

    Time frame: Up to 12 months

  5. Overall Survival(OS)

    The time between the first treatment date and the date of the patient's death due to any reason.

    Time frame: Up to 12 months

  6. The 6-month and 12-month overall survival (OS) rates.

    The 6-month and 12-month overall survival (OS) rates.

    Time frame: Up to 6 or 12 months

  7. The proportion and activation status of antigen-specific T cells in peripheral blood and tumor tissue (if available)

    The proportion and activation status of antigen-specific T cells in peripheral blood and tumor tissue (if available)

    Time frame: about 2 years

  8. The titers of antigen-specific antibodies IgG and IgA in serum

    The titers of antigen-specific antibodies IgG and IgA in serum

    Time frame: about 2 years

Other outcomes

  1. Copy number of BMD006 mRNA in serum

    Copy number of BMD006 mRNA in serum

    Time frame: about 2 years

  2. Circulating tumor DNA (ctDNA) levels in patients with advanced lung cancer or advanced solid tumors with lung metastasis.

    Circulating tumor DNA (ctDNA) levels in patients with advanced lung cancer or advanced solid tumors with lung metastasis.

    Time frame: about 2 years

  3. The incidence of dose-limiting toxicity (DLT) after treatment with BMD006 in combination with PD-1 antibody

    The incidence of dose-limiting toxicity (DLT) after treatment with BMD006 in combination with PD-1 antibody

    Time frame: about 2 years

  4. The incidence of Adverse Events (AEs) after treatment with BMD006 in combination with PD-1 antibody

    The incidence of Adverse Events (AEs) after treatment with BMD006 in combination with PD-1 antibody

    Time frame: about 2 years

  5. The proportion and activation status of antigen-specific T cells in peripheral blood and tumor tissue (if available) after treatment with BMD006 in combination with PD-1 antibody

    The proportion and activation status of antigen-specific T cells in peripheral blood and tumor tissue (if available) after treatment with BMD006 in combination with PD-1 antibody

    Time frame: about 2 years

  6. The titers of serum antigen-specific IgG and IgA antibodies following treatment with BMD006 in combination with Immuno-Oncology (IO) therapy

    The titers of serum antigen-specific IgG and IgA antibodies following treatment with BMD006 in combination with Immuno-Oncology (IO) therapy

    Time frame: about 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

Of 164 non-industry phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 90. This study's planned 24 months is below that.

Counting every sponsor, half of 294 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 15, 2025
StartActual
Feb 24, 2025
Primary completionEst.
Feb 24, 2027
CompletionEst.
Feb 24, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Biological: BMD006 monotherapy·Biological: BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation)·Biological: BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Expansion); removed Biological: BMD006 monotreatment·Biological: BMD006 in combination with PD-1 antibody·Biological: BMD006 in combination with PD-1/VEGF antibody. Arms added: BMD006 monotherapy·BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation)·BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Expansion); arms removed: BMD006 monotreatment·BMD006 in combination with PD-1or PD-1/VEGF antibody·BMD006 in combination with PD-1/VEGF antibody
Oct 26, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • Editedother outcomeThe titers of serum antigen-specific antibodies IgG and IgA in serum afterantibodies following treatment with BMD006 in combination with PDImmuno-1 antibodyOncology (IO) therapyTime frame: about 2 years
Oct 26, 2026
Title
Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine infor Advanced Lung Cancer and Lung MetastasisPulmonary Metastases of Solid Tumors.
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • Editedother outcomeThe titers of serum antigen-specific antibodies IgG and IgA in serum afterantibodies following treatment with BMD006 in combination with PDImmuno-1 antibodyOncology (IO) therapyTime frame: about 2 years
    Interventions Added Biological: BMD006 monotherapy·Biological: BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation)·Biological: BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Expansion); removed Biological: BMD006 monotreatment·Biological: BMD006 in combination with PD-1 antibody·Biological: BMD006 in combination with PD-1/VEGF antibody. Arms added: BMD006 monotherapy·BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation)·BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Expansion); arms removed: BMD006 monotreatment·BMD006 in combination with PD-1or PD-1/VEGF antibody·BMD006 in combination with PD-1/VEGF antibody
    Title Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine infor Advanced Lung Cancer and Lung MetastasisPulmonary Metastases of Solid Tumors.
    + 3 other changes: index terms, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06928922
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Feb 24, 2025
Primary completion
Feb 24, 2027 (estimated)
Completion
Feb 24, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Shuhang Wang, Doctor
Contact
snowflake201@163.com
+86135 8180 9307
Ning Li, Doctor
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion